GAITHERSBURG, Md., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company’s chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, ...

BETHESDA, Md., April 28 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc., a private biopharmaceutical company focused on the development of innovative vaccine products, announced today that results from ...

COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like ...

Study successfully met its primary endpoints Data from second pivotal Phase 3 study in people aged 12 to 64 years expected in the third quarter 2023 A total of 413 participants were enrolled and ...

Icosavax has drawn up clinical trial plans for its new type of vaccine in a strategy to commence tests of multiple programs, including a Covid-19 candidate. But really, the startup is following a path ...

TARRYTOWN, N.Y.--(BUSINESS WIRE)--TechnoVax, Inc., a biotechnology developer of novel vaccines, has received a one-year $509,623 SBIR grant from the National Institute of Allergy and Infectious ...

Icosavax has raised a $51 million series A round to take respiratory syncytial virus (RSV) vaccine IVX-121 through phase 1b in older adults. The vaccine is built on computationally designed ...

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulting in the COVID-19 pandemic, has pushed the world towards developing rushed but effective vaccines against the ...

The lung is a major entry point for many of the most detrimental pathogens to human health. The onslaught of pathogens encountered by the lung is counteracted by protective immune responses that are ...